NEW YORK, Dec. 8 (GenomeWeb News) - DynaMetrix and the Karolinska Institute announced yesterday that they have partnered with the National Cancer Institute's Cancer Genome Anatomy Project to validate probable causal SNPs that underline differences in protein sequences between individuals.
According to DynaMetrix and the Karolinska Institute, these non-synonymous sequence differences - or ns-cSNPs - may be responsible for much of the variation between people in terms of disease risk and drug response.
The partners said are using DynaMetrix's DASH-2 genotyping and diagnostic systems to validate the ns-cSNPs in sets of 12, using black and white individuals. Thereafter, DASH will be used to determine allele frequencey distributions in large global populations.
Information generated by the project will be made publicly available on a Cancer Genome Anatomy Project website.